Immunitybio Inc (IBRX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Immunitybio Inc stock (IBRX) is currently trading at $8.07. Immunitybio Inc PS ratio (Price-to-Sales) is 76.87. Analyst consensus price target for IBRX is $14.80. WallStSmart rates IBRX as Sell.
- IBRX PE ratio analysis and historical PE chart
- IBRX PS ratio (Price-to-Sales) history and trend
- IBRX intrinsic value — DCF, Graham Number, EPV models
- IBRX stock price prediction 2025 2026 2027 2028 2029 2030
- IBRX fair value vs current price
- IBRX insider transactions and insider buying
- Is IBRX undervalued or overvalued?
- Immunitybio Inc financial analysis — revenue, earnings, cash flow
- IBRX Piotroski F-Score and Altman Z-Score
- IBRX analyst price target and Smart Rating
Immunitybio Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Immunitybio Inc (IBRX) · 5 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth. Concerns around operating margin and price/sales. Significant fundamental concerns warrant caution or avoidance.
Immunitybio Inc (IBRX) Key Strengths (2)
Revenue surging 407.00% year-over-year
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Immunitybio Inc (IBRX) Areas to Watch (3)
Losing money on operations
Very expensive at 76.9x annual revenue
Low institutional interest, mostly retail-driven
Supporting Valuation Data
Immunitybio Inc (IBRX) Detailed Analysis Report
Overall Assessment
This company scores 21/100 in our Smart Analysis, earning a F grade. Out of 5 metrics analyzed, 2 register as strengths (avg 8.5/10) while 3 fall into concern territory (avg 2.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Market Cap. Growth metrics are encouraging with Revenue Growth at 407.00%.
The Bear Case
The primary concerns are Operating Margin, Price/Sales, Institutional Own.. Some valuation metrics including Price/Sales (76.87) suggest expensive pricing. Profitability pressure is visible in Operating Margin at -169.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Operating Margin at -169.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 407.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Operating Margin and Price/Sales are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
IBRX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
IBRX's Price-to-Sales ratio of 76.87x trades at a deep discount to its historical average of 3541.91x (11th percentile). The current valuation is 99% below its historical high of 9398.21x set in Jul 2023, and 347% above its historical low of 17.21x in Dec 2025. Over the past 12 months, the PS ratio has compressed from ~209.8x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Immunitybio Inc (IBRX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Immunitybio Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 113M with 407% growth year-over-year.
Key Findings
Revenue growing at 407% YoY, reaching 113M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 54% of revenue (61M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -71M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Immunitybio Inc maintain 407%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Immunitybio Inc.
Bottom Line
Immunitybio Inc is a high-conviction growth story with revenue accelerating at 407% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(47 last 3 months)
| Insider | Type | Shares |
|---|---|---|
SIMON, BARRY J. Director | Sell | -75,000 |
| Insider | Type | Shares |
|---|---|---|
SIMON, BARRY J. Director | Sell | -10,000 |
Data sourced from SEC Form 4 filings
Last updated: 10:05:35 AM
About Immunitybio Inc(IBRX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
ImmunityBio, Inc., an immunotherapy company, develops a memory T-cell cancer vaccine to fight multiple types of tumors without the use of high-dose chemotherapy.